Our pathway analysis showed that not only point mutations, and deletion of TP53 itself are important in cancer predisposition in C-AYA patients, but also that P/LP germline mutations of other, seemingly disparate, genes point to a final common disruption of the p53 pathway. The gene discussed is TP53; the disease is cancer.